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Abstract. In this study, we assessed whether cerebrospinal fluid (CSF) levels of the biomarker α-synuclein have a diagnostic
value in differential diagnosis of dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). We also analyzed associations
between CSF biomarkers and cognitive performance in DLB and in AD. We included 35 DLB patients, 63 AD patients, 18 patients
with Parkinson’s disease (PD), and 34 patients with subjective complaints (SC). Neuropsychological performance was measured
by means of the Mini-Mental Status Examination (MMSE), Visual Association Test (VAT), VAT object-naming, Trail Making
Test, and category fluency. In CSF, levels of α-synuclein, amyloid-β 1-42 (Aβ1−42), total tau (tau), and tau phosphorylated at
threonine 181 (ptau-181) were measured. CSF α-synuclein levels did not differentiate between diagnostic groups (p = 0.16).
Higher ptau-181 and higher tau levels differentiated AD from DLB patients (p < 0.05). In DLB patients, lower Aβ1−42 and
higher total tau levels were found than in SC and PD patients (p < 0.05). In DLB patients, linear regression analyses of CSF
biomarkers showed that lower α-synuclein was related to lower MMSE-scores (β(SE) = 6(2) and p < 0.05) and fluency (β
(SE) = 4(2), p < 0.05). Ultimately, CSF α-synuclein was not a useful diagnostic biomarker to differentiate DLB and/or PD
(α-synucleinopathies) from AD or SC. In DLB patients maybe lower CSF α-synuclein levels are related to worse cognitive
performance.
Keywords: Alzheimer’s disease, biomarkers, cerebrospinal fluid, dementia with Lewy bodies, diagnosis, α-synuclein
INTRODUCTION
Dementia with Lewy bodies (DLB) is the second
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most common form of neurodegenerative dementia af-
ter Alzheimer’s disease (AD) [1]. In pathological stud-
ies, DLB accounts for more than 20% of dementia
cases [2,3]. Clinical hallmarks are cognitive decline
accompanied by parkinsonism, visual hallucinations,
and fluctuating cognitive performance and conscious-
ness [2,4]. Unfortunately, diagnostic criteria have mod-
est sensitivity and it can be difficult to differentiate
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DLB from other forms of dementia, especially AD [2,
4,5]. Correct diagnosis is important for adequate clin-
ical management. Next to clinical characteristics, an-
cillary investigations can aid in making the correct di-
agnosis [6]. For DLB, it has been shown that 123I-
FP-CIT-SPECT can distinguish this disease from AD
with quiet high accuracy in probable cases [7]. But its
value in possible DLB is less clear and SPECT is rather
expensive so there is rationale to explore other markers
related to the underlying pathology.
Analysis of CSF biomarkers is increasingly applied
in the diagnostic work-up of neurodegenerative dis-
ease. Especially in AD, a typical profile is observed
with decreased CSF amyloid-β 1-42 (Aβ1−42) and in-
creased total tau protein (tau) and tau phosphorylated
at threonine 181 (ptau-181) when compared to con-
trols [8]. These CSF biomarkers reflect the main neu-
ropathological features of AD, i.e., Aβ and tau depo-
sitions. There are no generally accepted biomarkers to
distinguish DLB from other types of dementia. Typical
neuropathological changes in DLB are the formation
of Lewy bodies, consisting of insoluble α-synuclein
and ubiquitin depositions and aggregation [9]. These
findings are also seen in Parkinson’s disease (PD) and
multiple system atrophy (MSA), collectively labeled as
α-synucleinopathies [9]. Since α-synuclein was found
in CSF and plasma, several studies suggest that CSF
α-synuclein may serve as a biomarker to differentiate
α-synucleinopathies from other neurodegenerative dis-
eases [10,11]. Conflicting results have been described,
however, since some studies observed reduced levels
of CSF α-synuclein in PD and DLB compared to con-
trols [12,13], whereas in other studies no differences
between groups were found [14,15]. Finally, lower
levels of CSF α-synuclein have been reported in AD-
patients compared to controls, suggesting it may be a
general marker of synapse loss [16].
Our aim was to determine the diagnostic value of
CSF α-synuclein levels to discriminate DLB and PD
(α-synucleinopathies) from AD and controls in a rel-
atively large group of clinically well-characterized pa-
tients. In addition, we investigated associations be-
tween CSF biomarkers and severity of cognitive im-
pairment in AD and DLB.
MATERIALS AND METHODS
Patients
We selected patients from which CSF was available
with probable DLB and PD without dementia from
our outpatient memory clinic and movement disorder
clinic database. Eighteen PD and 35 DLB patients
were retrieved. DLB patients were matched for age
and gender with 63 probable AD patients and with 34
controls. The diagnosis was made by consensus in a
multidisciplinary team, without knowledge of CSF re-
sults. DLB patients were diagnosed according to the
consensus criteria of McKeith, PD according to the UK
Parkinson’s Disease Society Brain Bank (UK-PDSBB)
clinical diagnostic criteria, and AD patients according
to NINCDS-ADRDA criteria [4,17,18]. The control
group consisted of patients who presented at our mem-
ory clinic with subjective complaints (SC), but who
had normal clinical investigations and did not have any
cognitive deficits. Standardized assessment included
medical history, informant-based history, physical and
neurological exam, laboratory tests, neuropsycholog-
ical testing, and magnetic resonance imaging (MRI).
In PD patients the Hoehn and Yahr scale, a five-point
rating system to stage PD (1 = mild, 5 = very severe)
was used to reflect severity of symptoms [19]. The
Neuropsychiatric inventory (NPI), a 12-item caregiver
questionnaire was used to assess behavioral and psy-
chological symptoms of dementia [20]. The local eth-
ical review board approved the study and all patients
gave written informed consent.
CSF analysis
CSF was obtained by lumbar puncture between the
L3/L4 or L4/L5 intervertebral space, using a 25-gauge
needle and collected in polypropylene tubes. Within
two hours, CSF samples were centrifuged at 1800 g
for 10 min at 4◦C. A small amount of CSF was used
for routine analysis, including total cells (erythrocytes
and leukocytes), total protein, and glucose. Erytro-
cytes were measured, as these are a known source of
α-synuclein in blood [21]. Excess CSF erythrocytes
(e.g., due to traumatic puncture) could therefore po-
tentially confound CSF α-synuclein-levels. CSF was
aliquoted in polypropylene tubes of 0.5 or 1 ml and
stored at−80◦C until further analysis. The technicians
performing the analysis did not have access to the clin-
ical data. CSF Aβ1−42, tau and ptau-181 concentra-
tions were determined, using commercially available
ELISAs [22].
The α-synuclein assay is based on a previously de-
scribed procedure [23]. Currently, 4 isoforms of α-
synuclein are known [24]. Isoform α-synuclein-140
comprises the whole transcript of the protein. The other
3 isoforms, α-synuclein-126, α-synuclein-112, and α-
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synuclein-98, are the result of alternative splicing caus-
ing in-frame deletions of exon 3 (amino acids 41–54)
and exon 5 (103–130), and both exon 3 and 5, respec-
tively [24,25]. In the current assay, both α-synuclein-
112 andα-synuclein-98 isoforms are not routinely mea-
sured.
A disposable flat-bottom microtiterplate (Nunc Max-
isorp F96, Roskilde, Denmark) was coated with 100
µl antibody 211 (0.2 µg/ml in 0.20 M carbonate buffer
pH 9.6) overnight at 4◦C. A plate washer (BioTek, Be-
un de Ronde, Abcoude The Netherlands) was used to
wash the plate five times with 250 µl PBS containing
0.05% Tween-20 (PBS washing buffer). All further
incubations were performed at 37◦C, unless stated oth-
erwise, and all measurements were performed in dupli-
cate. 250 µl of blocking buffer (2.5% gelatin in PBS
washing buffer) was added and incubated for 2 hr and
the plate was subsequently washed for five times with
PBS washing buffer. Next, 100µlα-synuclein solution
(from 0 to 500 ng/ml diluted in PBS) or CSF (1:2 di-
luted in PBS) was added to each well and incubated for
2.5 hr (in duplicate). Then, the plate was washed five
times with PBS washing buffer, and 100 µl of antibody
FL-140, diluted 1:1000 in blocking buffer, was added
for 1.5 hr. Again, the plate was washed five times and
100 µl of the peroxidase labeled goat-anti rabbit an-
tibody (dilution 1:5000 in blocking buffer) was added
and incubated for 1 hr. After a final washing step 100µl
of a freshly prepared solution of tetramethyl benzidine
(TMB) was applied and incubated for 15 min in the
dark at room temperature. The reaction was stopped by
addition of 50 µl 2 N H2SO4 and the absorbance was
measured at 450 nm in an ELISA plate reader (Tecan
Sunrise, Salzburg, Austria). The lower detection limit
of the method was 3.8 ng/ml. The intra-assay coeffi-
cient of variation (CV) was 14.9% at a concentration of
17 ng/ml (n = 10), 3.5% at a concentration of 49 ng/ml
(n = 10) and 5.3% at a concentration of 85 ng/ml (n =
10). The inter-assay CV was 11.4% at a concentration
of 88 ng/ml (n = 13) and 15.0% at a concentration of
66 ng/ml (n = 16). We excluded 6 outliers (3 AD pa-
tients, 2 SC and 1 PD patient) with α-synuclein levels
higher than 100 ng/ml. This exclusion did not alter the
outcome of this study (data not shown).
Neuropsychological tests
The neuropsychological test battery was designed
to screen the major cognitive functions and included
the following tests. Mini-Mental State Examination
(MMSE) was used as a measure of global cognitive
function [26]. For memory, the Visual Association Test
(VAT) was used (range 0–12) [27]. VAT object naming
was used as a measure for language (0–12). The Trail
making Test (TMT) consists of a simple part A and a
more complex part B, used to evaluate executive func-
tioning [28]. In TMT the measure of mental speed and
the time required for completion is recorded. Catego-
ry fluency is a test of executive function and language
and requires verbal production of as many animals as
possible within a time limit of 60 s. Only 8 PD pa-
tients underwent neuropsychological testing; these da-
ta were not analyzed. Neuropsychological test results
were missing for a number of patients: MMSE 3 cases,
VAT 15 cases, VAT object naming 19 cases, TMT-A
scores 18 cases, TMT-B scores 36 cases and category
fluency 15 cases.
Statistical analysis
For statistical analysis, Statistical Package of the So-
cial Science (SPSS), version 15.0, was used. CSF
biomarkers and TMT scores were log-transformed.
Group comparisons were performed using chi-squared
tests for categorical data and for continuous data we
used analysis of variance (ANOVA), corrected for age
and gender, with post-hoc Bonferroni tests. Correla-
tions were assessed using bivariate Pearson correla-
tion coefficient. To assess associations between CSF
biomarkers and neuropsychological tests in dementia,
linear regression analyses were performed. We per-
formed linear regression analyses separately for DLB
patients and AD patients. CSF biomarkers were entered
as independent variable and neuropsychological test re-
sults as dependent variables. In the first model each
biomarker was entered separately, with age and gender
as covariates. In the second model, CSF biomarkers
were entered simultaneously, with age and gender as
covariates. Due to colinearity between tau and ptau-
181 models contained three biomarkers (i.e., Aβ1−42,
α-synuclein, tau or Aβ1−42, α-synuclein, ptau-181).
Statistic significance was set at p < 0.05.
RESULTS
Demographic data, CSF biomarkers concentrations
and neuropsychological test results are presented by
diagnostic group in Table 1. There were group differ-
ences in age and the distribution of gender (p < 0.05).
Post hoc testing showed that DLB patients were old-
er than SC and PD patients. The proportion of males
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Table 1
Clinical data, neuropsychological test results and CSF biomarkers by diagnostic group
SC (n = 34) PD (n = 18) DLB (n = 35) AD (n = 63)
Age 67 ± 5 67 ± 8 71 ± 8a,b 69 ± 7
Female 16 (44%) 8 (42%) 6 (17%)a,d 34 (52%)
α-Synuclein (ng/ml) 18 (14–26) 23 (18–32) 20 (15–27) 16 (13–23)
Aβ1−42(pg/ml) 823 (661–1018)c,d 875 (719–987)c,d 479 (386–661)a,b 484 (387–545)a,b
Tau (pg/ml) 252 (208–354)c,d 196 (130–268)c,d 382 (265–574)a,b,d 613 (416–897)a,b,c
Ptau-181 (pg/ml) 48 (38–56)d 49 (37–60)d 53 (42–72)d 82 (63–1143)a,b,c
MMSE 28 ± 1c,d 29 ± 1c,d 21 ± 5a,b 21 ± 4a,b
VAT 12 ± 1c,d − 7 ± 4a 5 ± 4a
Naming 12 ± 0d − 12 ± 1 11 ± 2a
TMT-A 41 ± 13c,d − 119 ± 82a 103 ± 82a
TMT-B 100 ± 41c,d − 416 ± 190a,d 240 ± 124a,c
Fluency 24 ± 5c,d - 12 ± 5a 12 ± 5a
Data are expressed as mean ± SD, median (I-Q range), n (%). Differences between groups were assessed
with ANOVA, adjusted for age and gender. Biomarkers and TMT are presented as raw data, but statistics were
performed using log-transformed data. SC: subjective complaints, PD: Parkinson’s disease, DLB: Dementia with
Lewy bodies, AD: Alzheimer’s disease, MMSE: mini-mental state examination, VAT: Visual Association Test,
Naming: VAT object naming, TMT: Trail Making Test, Fluency: Category fluency. ap < 0.05 compared to SC.
bp < 0.05 compared to PD. cp < 0.05 compared to DLB. dp < 0.05 compared to AD.
was higher in patients with DLB than SC patients and
patients with AD.
CSF α-synuclein levels, adjusted for age and gender,
were not different among diagnostic groups (p = 0.16,
see also Fig. 1). In our data the reference range for
controls had a median (interquartile range) of 18 ng/ml
(14–26 ng/ml). As expected, there were group differ-
ences for CSF Aβ1−42, tau and ptau-181 (p < 0.05).
DLB patients had a profile with decreased Aβ1−42 and
increased tau compared to SC and PD patients. Aβ1−42
levels were similar, but tau levels were lower in DLB
patients compared to AD patients. AD patients had
an increased ptau-181 level compared to DLB patients.
SC and PD patients had no differences in biomarker
levels.
Neuropsychological test results by diagnostic group
are shown in Table 1. As expected patients with demen-
tia (DLB and AD) performed worse in all neuropsy-
chological tests, except VAT object naming, which was
only reduced in AD patients. DLB patients were slower
on TMT-B than patients with AD.
Across groups we found no association between CSF
α-synuclein and age, gender, disease duration, or CSF
storage time. Hoehn and Yahr-scores had a tendency
of negative correlation with CSF α-synuclein levels in
PD patients (r = − 0.25, p = 0.3). NPI-scores for hal-
lucinations had a tendency to be negatively correlated
with CSF α-synuclein levels in DLB (r = − 0.25, p =
0.2). We found positive correlations between CSF α-
synuclein levels and CSF total protein and erythrocytes
(both r = 0.27, p = 0.01). When we reanalyzed our
data, with exclusions of samples with CSF erythrocytes
more than 500 erythrocytes per µl (n = 18) and CSF
protein more than 500 per µl (n = 24), there were no
essential changes in outcomes.
CSF Aβ1−42, tau, and ptau-181 were not correlat-
ed with age, disease duration, CSF total protein, stor-
age time or erythrocytes (data not shown). CSF α-
synuclein levels did not correlate with other biomarkers
across groups: Aβ42 (r = 0.04, p = 1.0), tau (r = −
0.13, p = 0.10) or ptau-181 (r = − 0.13, p = 0.10).
Subsequently, we assessed associations between
CSF biomarker levels and performance on neuropsy-
chological tests in DLB and AD, using linear regression
analyses (Table 2). Adjusted for age and gender (Mod-
el 1), MMSE-score was related to lower levels of CSF
α-synuclein (see also Fig. 2) and higher levels of tau
and ptau-181 in DLB-patients. Furthermore, impaired
performance on the VAT was related to higher levels
of tau and impaired object naming was related with
lower Aβ1−42 levels. When we entered all biomarkers
simultaneously in the second model, relationships with
tau disappeared. Additionally, lower α-synuclein was
also related to worse category fluency. In AD patients
we observed a different picture. Worse performance on
the VAT was related to higher levels of tau, but there
were no associations between Aβ42 CSF α-synuclein
and cognitive performance.
DISCUSSION
We found no differences in levels of α-synuclein in
CSF between DLB, PD, AD, and SC. However, lower
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Table 2
Linear regression between biomarkers and neuropsychological performance in dementia (DLB, AD)
DLB AD
β (SE) α-Syn Aβ 1−42 Tau Ptau-181 α-Syn Aβ 1−42 Tau Ptau-181
MMSE 1 6 (2)∗ 4 (3) −5 (2)∗ −4 (2)∗ −1 (1) 2 (2) 0 (1) 1 (1)
2 5 (2)∗ 1 (3) −4 (2) −3 (2) −1 (1) 1 (2) 1 (1) 1 (1)
VAT 1 −1 (2) 5 (3) −4 (2)∗ −4 (2) 0 (1) 2 (1) −2 (1)∗ −2 (1)
2 −1 (2) 2 (3) −4 (2) −3 (2) 0 (1) 1 (2) −2 (1) −1 (1)
Naming 1 0 (0) 1 (0)∗ −1 (0)∗ 0 (0) 0 (1) 1 (1) −1 (1) −1 (1)
2 0 (0) 1 (1)∗ 0 (0) 0 (0) 0 (1) 1 (1) −1 (1) −1 (1)
TMT-A 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
TMT-B 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fluency 1 3 (2) 4 (2) −3 (2) −3 (2) −2 (2) 1 (2) −1 (1) −1 (2)
2 4 (2)∗ 3 (3) −1 (2) −1 (2) −1 (2) 0 (2) 0 (1) 0 (2)
Numbers represent regression coefficients (standard error) from linear regression analysis. Model 1: Each separate
biomarker level was entered separately in a model together with age and gender. Model 2: Biomarker levels (α-
synuclein, Aβ1−42 and tau) were entered into one model with age and gender. Due to colinearity with tau, ptau-181
levels were entered into one model with α-synuclein, Aβ1−42 and age and gender. *p < 0.05 DLB: Dementia
with Lewy bodies, AD: Alzheimer’s disease, MMSE: Mini-Mental State Examination, VAT: Visual Association Test,
Naming: VAT object naming, TMT: Trail Making Test, Fluency: Category fluency.
Fig. 1. Box and whisker plots of log transformed CSF α-synuclein levels (ng/ml) by diagnostic group. Patients with Parkinson’s disease (PD)
(n = 18), dementia with Lewy bodies (DLB) (n = 35), Alzheimer’s disease (AD) (n = 63), and subjective complaints (SC) (n = 34). The
line through the middle of the boxes corresponds to the median and the lower and the upper lines to the 25th and 75th percentile respectively.
The whiskers extend from the 5th percentile on the bottom to the 95th percentile on top. Group comparisons were performed using analysis of
variance (ANOVA), corrected for age and gender. CSF α-synuclein levels, adjusted for age and gender, were not different among the diagnostic
groups (p = 0.16).
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Fig. 2. A) Scatterplot of the distribution of log transformed CSF α-synuclein levels (ng/ml) and MMSE in patients with DLB. The X-axis shows
the MMSE scores and the Y-axis the CSF α-synuclein levels. The MMSE and CSF α-synuclein levels have a positive association in the DLB
group, as shown by linear regression analysis with age and gender as covariates (β = 6(2), p < 0.05). B) Scatterplot of the distribution of log
transformed CSF α-synuclein levels (ng/ml) and MMSE in patients with AD. The MMSE and CSF α-synuclein levels have no association in the
AD group, as shown by linear regression analysis with age and gender as covariates (β = − 1(1), p = 0.35).
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CSF α-synuclein levels were related to worse cognitive
performance in DLB patients. Our findings suggest
that CSF α-synuclein is not a useful biomarker to dis-
tinguish DLB and/or PD from AD and SC. A possible
explanation could be that CSF α-synuclein does not
reflect the disease process in α-synucleinopathies. The
pathological hallmark of this group of diseases is the
Lewy body, an intracytoplasmatic inclusion body that
contains aggregates of insolubleα-synuclein. It has not
been elucidated yet what the exact relationship is be-
tween intracellular α-synuclein aggregates and extra-
cellular α-synuclein levels. CSF levels of α-synuclein
represent the pool of extracellular α-synuclein secret-
ed by neurons, but it is not known if the concentration
changes in pathological situations as it does for Aβ.
Another potential confounding factor is overlap in
histopathology in neurodegenerative diseases. Neu-
ropathological studies reported the presence of α-
synuclein pathology in brains of AD patients in around
60% of cases [29]. A decrease of CSF α-synuclein
levels in AD patients compared to controls has been
described [16]. α-Synuclein pathology has also been
found in brain tissue of 10–37% of aged healthy con-
trols although the load seems to be much higher in
PD/DLB [3,30]. This ‘mixed pathology’ could explain
why the levels of α-synuclein could not discriminate
between DLB/PD and AD.
In this study, DLB patients had decreased CSF
Aβ1−42 and increased tau compared to PD and SC pa-
tients. Tau levels in DLB were less elevated than in
AD patients. This has been described by other and is
in line with histopathological findings [31,32]. Most
DLB patients have sufficient amyloid plaques to meet
the pathological criteria of AD, although few patients
display severe diffuse tangle pathology to reach Braak
stages V or VI [33]. Ptau-181 levels were solely elevat-
ed in AD, underscoring the results of previous studies
that this marker can be used to discriminate between
AD and DLB [34].
Our results are in agreement with recent studies in
which CSF α-synuclein concentrations did not differ
betweenα-synucleinopathies and healthy controls [14–
16]. In contrast, two earlier studies described lower
levels of α-synuclein in CSF of PD and DLB patients
compared to controls and AD patients [12,13]. An ex-
planation for these discrepant results could be the use
of different antibodies, possibly binding to different
parts of the α-synuclein protein. Also these discrepan-
cies could be partly due to the application of different
assays. The assay of Tokuda et al. required protein-
enriched CSF [12] and the assay of Mollenhauer et al.
required elongated incubation (48 hr at 4◦C) of uncon-
centrated CSF [13].
To our knowledge, this is the first study that investi-
gates the relation between neuropsychological data oth-
er than the MMSE and CSF α-synuclein levels. Lower
CSF α-synuclein levels were related to worse cogni-
tive performance (MMSE, category fluency) in DLB
patients in the present study. This is in agreement with
a recent finding by Ballard et al., who found a positive
correlation between the CSF α-synuclein and MMSE
in 12 DLB-patients [35]. Ohrfelt et al. found results
of lower CSF α-synuclein related to worse MMSE in
AD patients [16]. Although MMSE-scores were com-
parable between DLB and AD patients we could not
replicate this finding. If CSF α-synuclein is related to
neuronal pathological aggregation of α-synuclein, the
observed correlation between CSF α-synuclein levels
and MMSE in DLB patients possibly reflects disease
severity. When biomarkers were assessed separately
in DLB, associations between cognitive performance
and lower levels of Aβ1−42 and higher tau were found.
This suggests a synergistic effect of AD-pathology in
DLB. In AD patients, tau was related to worse memory
performance. This is comparable with previous studies
which suggested that higher levels of CSF tau reflects
the intensity of the disease process in AD [36,37].
This study contributes to the still sparse literature on
CSF α-synuclein and shows that this protein is not a
reliable diagnostic biomarker for DLB, at least when
using an immunosorbent assay designed by Van Geel
et al. [23] Further investigation is needed to determine
technical aspects of the assays and the specific species
and isoforms of CSF α-synuclein that might be de-
tected. Several studies support the idea that soluble
oligomers of CSF α-synuclein are the pathogenic com-
ponents that drive neurodegeneration and neuronal cell
death [38]. Future studies focus on the detection of
these solubleα-synuclein oligomers and a novel ELISA
method has recently been described [39].
DLB is clinically a heterogeneous disease and in-
volves several neuropathological processes. In view of
the current suboptimal diagnostic accuracy, a biomark-
er that would provide early and correct diagnosis would
be an asset. It has to be further clarified how ‘mixed
pathology’ is reflected in the CSF and how this influ-
ences the diagnostic ability of CSF biomarkers.
The tendency of CSF α-synuclein to be related to
cognitive performance in DLB and AD needs additional
investigation, as to how this associates with underlying
neurodegenerative processes.
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